Literature DB >> 12824873

Parp-1 deficiency implicated in colon and liver tumorigenesis induced by azoxymethane.

Tadashige Nozaki1, Hisako Fujihara, Masatoshi Watanabe, Masahiro Tsutsumi, Kentaro Nakamoto, Osamu Kusuoka, Nobuo Kamada, Hiroshi Suzuki, Hitoshi Nakagama, Takashi Sugimura, Mitsuko Masutani.   

Abstract

Poly(ADP-ribose) polymerase-1 (Parp-1) is activated by DNA strand breaks and functions in the maintenance of genomic integrity and cell death control. On the other hand, Parp-1 is also involved in transcriptional regulation of various genes, and the relationship between Parp-1 deficiency and susceptibility to tumorigenesis has not been fully elucidated. In the present study, Parp-1(-/-) mice, harboring exon 1 disruption in Parp-1, and Parp-1(+/+) animals were administered azoxymethane (AOM) at a dose of 10 mg/kg body weight once a week for 6 weeks. At 30 weeks after the first carcinogen treatment, mice were sacrificed. The incidence of animals bearing either adenomas or adenocarcinomas in the colon and the average number of colon tumors per mouse were significantly higher in Parp-1(-/-) mice than in Parp-1(+/+) animals. beta-Catenin accumulation was observed in 43/44 of Parp-1 (-/-) tumors and 19/21 of the Parp-1(+/+) tumors and was not statistically different between the genotypes. This suggests that most tumors developed through a pathway involving the alteration of Wnt-beta-catenin signaling in both Parp-1(-/-) and Parp-1(+/+) mice. In the liver, where AOM is primarily activated, the incidence of animals bearing nodules and the average number of nodules per section were significantly increased in Parp-1(-/-) mice compared with Parp-1(+/+) mice. Therefore, the results indicate that susceptibility to AOM-induced tumorigenesis in the colon and also in the liver is enhanced in Parp-1(-/-) mice, and Parp-1 could have a substantial role in colon and liver tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12824873     DOI: 10.1111/j.1349-7006.2003.tb01472.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  18 in total

1.  Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis.

Authors:  Hongping Yu; Hongxia Ma; Ming Yin; Qingyi Wei
Journal:  Genet Epidemiol       Date:  2011-11-29       Impact factor: 2.135

Review 2.  Two DNA repair gene polymorphisms on the risk of gastrointestinal cancers: a meta-analysis.

Authors:  Yue Hu; Min Zhou; Kang Li; Kai Zhang; Xiangquan Kong; Yamei Zheng; Jianxu Li; Li Liu
Journal:  Tumour Biol       Date:  2013-11-08

Review 3.  Opportunities for the repurposing of PARP inhibitors for the therapy of non-oncological diseases.

Authors:  Nathan A Berger; Valerie C Besson; A Hamid Boulares; Alexander Bürkle; Alberto Chiarugi; Robert S Clark; Nicola J Curtin; Salvatore Cuzzocrea; Ted M Dawson; Valina L Dawson; György Haskó; Lucas Liaudet; Flavio Moroni; Pál Pacher; Peter Radermacher; Andrew L Salzman; Solomon H Snyder; Francisco Garcia Soriano; Robert P Strosznajder; Balázs Sümegi; Raymond A Swanson; Csaba Szabo
Journal:  Br J Pharmacol       Date:  2017-03-26       Impact factor: 8.739

4.  Loss of PIDD limits NF-κB activation and cytokine production but not cell survival or transformation after DNA damage.

Authors:  F J Bock; G Krumschnabel; C Manzl; L Peintner; M C Tanzer; N Hermann-Kleiter; G Baier; L Llacuna; J Yelamos; A Villunger
Journal:  Cell Death Differ       Date:  2012-12-14       Impact factor: 15.828

Review 5.  Trial watch - inhibiting PARP enzymes for anticancer therapy.

Authors:  Antonella Sistigu; Gwenola Manic; Florine Obrist; Ilio Vitale
Journal:  Mol Cell Oncol       Date:  2015-06-10

6.  PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.

Authors:  Xue Mei Jin; Hee Nam Kim; Il-Kwon Lee; Kyeong-Soo Park; Hyeoung-Joon Kim; Jin-Su Choi; Sang Woo Juhng; Chan Choi
Journal:  BMC Med Genet       Date:  2010-03-03       Impact factor: 2.103

7.  Role of nicotinamide in DNA damage, mutagenesis, and DNA repair.

Authors:  Devita Surjana; Gary M Halliday; Diona L Damian
Journal:  J Nucleic Acids       Date:  2010-07-25

8.  Adiponectin deficiency enhances colorectal carcinogenesis and liver tumor formation induced by azoxymethane in mice.

Authors:  Tamao Nishihara; Miyako Baba; Morihiro Matsuda; Masahiro Inoue; Yasuko Nishizawa; Atsunori Fukuhara; Hiroshi Araki; Shinji Kihara; Tohru Funahashi; Shinji Tamura; Norio Hayashi; Hiroyasu Iishi; Iichiro Shimomura
Journal:  World J Gastroenterol       Date:  2008-11-14       Impact factor: 5.742

9.  PARP-1 protects against colorectal tumor induction, but promotes inflammation-driven colorectal tumor progression.

Authors:  Bastian Dörsam; Nina Seiwert; Sebastian Foersch; Svenja Stroh; Georg Nagel; Diana Begaliew; Erika Diehl; Alexander Kraus; Maureen McKeague; Vera Minneker; Vassilis Roukos; Sonja Reißig; Ari Waisman; Markus Moehler; Anna Stier; Aswin Mangerich; Françoise Dantzer; Bernd Kaina; Jörg Fahrer
Journal:  Proc Natl Acad Sci U S A       Date:  2018-04-09       Impact factor: 11.205

10.  Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women.

Authors:  Andrzej Roszak; Margarita Lianeri; Anna Sowińska; Paweł P Jagodziński
Journal:  Mol Diagn Ther       Date:  2013-08       Impact factor: 4.074

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.